NET4CGD Newsletter 2016 : Focus on the Gene Therapy Studies for X-CGD

The Net4CGD European Consortium is focused on the clinical development of Gene Therapy as a new Orphan Drug for patients with the X-linked form of Chronic Granulomatous Disease (X-CGD). Patients will receive autologous CD34+ blood stem cells transduced with the G1XCGD lentiviral vector. In 2016, Phase I/II Clinical Trials are ongoing in several clinical centers in Europe. For more information, please refer to the Net4CGD Newsletter 2016 that can be found here.